江西新贛江藥業股份有限公司成立于2004年，2023年2月在北交所掛牌上市（證券簡稱：新贛江，證券代碼：873167），公司注冊資金7086.125萬元，是一家集化學原料藥、化學藥品制劑及中成藥的研發、生產與銷售為一體的國家高新技術企業、省級民營企業、省級技術中心企業。公司原料藥產品主要為葡萄糖酸鈣、葡萄糖酸鋅、葡萄糖酸亞鐵等葡萄糖酸鹽系列原料藥，市場份額位居行業前列；公司主要化學藥品制劑為維生素C咀嚼片、復方銀翹氨敏膠囊、酚氨咖敏片等，屬于維生素類用藥和感冒類用藥；主要中成藥為心腦康膠囊、感冒靈膠囊、兒寶膏，屬于心腦血管類用藥、感冒類用藥和補益類用藥。
      自成立以來，公司就高度重視研發工作，始終把“務實創新”作為企業的文化理念。公司已建立一支專業的研發團隊，專注于藥學研究、新藥開發與生產工藝的改進提升。截至2023年12月31日，公司擁有技術人員共22人，占2023年末公司總人數的5.61%。目前公司共有在研項目14個，涵蓋消化道類、心腦血管類、感冒類、維生素類等多個領域，專注于仿制藥的研發與生產工藝的改進。公司積極與外部CRO建立合作關系，充分借助科研機構技術力量開展研發合作，實現優勢互補。

 

    Introduction to Jiangxi XinGanJiang Pharmaceutical Co., Ltd.

    Jiangxi XinGanJiang Pharmaceutical Co., Ltd. was established in 2004 and was listed on the Beijing Stock Exchange in February 2023 (stock abbreviation: XinGanJiang, stock code: 873167). The company has a registered capital of 70.86125 million yuan and is recognized as a national high-tech enterprise, a provincial-level private enterprise, and a provincial-level technology center enterprise.

    The company specializes in the research, development, production, and sales of Active Pharmaceutical Ingredient, chemical drug formulations, and traditional Chinese medicine. Its main raw material products include calcium gluconate, zinc gluconate, and ferrous gluconate, which are part of the gluconate series and hold a leading market share in the industry. The primary chemical drug formulations include vitamin C chewable tablets, compound Yinqiao antihistamine capsules, and phenylephrine and acetaminophen tablets, which fall under the categories of vitamin medications and cold remedies. The main traditional Chinese medicines include Xinnaokang capsules, Ganmaoling capsules, and Erbao ointment, which are classified as cardiovascular medications, cold remedies, and tonics.

    Since its inception, the company has placed a strong emphasis on research and development, consistently adhering to the cultural philosophy of "pragmatic innovation." A professional R&D team has been established, focusing on pharmaceutical research, new drug development, and the improvement of production processes. As of December 31, 2023, the company employs 22 technical personnel, accounting for 5.61% of the total workforce. Currently, there are 14 ongoing research projects covering various fields, including gastrointestinal, cardiovascular, cold remedies, and vitamins, with a focus on the development and process improvement of generic drugs. The company actively collaborates with external Contract Research Organizations (CROs) to leverage the technical capabilities of research institutions, achieving complementary advantages in research and development.